<DOC>
	<DOCNO>NCT00369941</DOCNO>
	<brief_summary>This study investigate safety efficacy MK-0518 versus efavirenz , combination TRUVADA , therapy Human Immunodeficiency Virus ( HIV ) -infected patient previously treat .</brief_summary>
	<brief_title>A Study Evaluate Safety Antiretroviral Activity MK-0518 Versus Efavirenz Treatment Naive HIV-Infected Patients , Each Combination With TRUVADA ( 0518-021 EXT )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Participant male female least 18 year age Participant HIV positive Participant na√Øve antiretroviral therapy ( ART ) receive ART Participant receive approved experimental antiretroviral agent past Participant treat viral infection HIV hepatitis B virus infection agent active HIV include limited adefovir lamivudine ( = 7 day total ) Participant document resistance tenofovir , emtricitabine , and/or efavirenz Participant use another experimental HIVintegrase inhibitor Participant current ( active ) diagnosis acute hepatitis due cause Participants chronic hepatitis include chronic hepatitis B and/or C may enter study long stable liver function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>